S0B1436 Anti-human Claudin 18.2 Monoclonal Antibody (zolbetuximab)
- 公司名稱(chēng) 杭州斯達(dá)特生物科技有限公司
- 品牌 Starter/斯達(dá)特
- 型號(hào) S0B1436
- 產(chǎn)地 浙江 杭州
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/8/10 10:10:14
- 訪問(wèn)次數(shù) 82
聯(lián)系方式:王修明13774214275 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息,謝謝!
Claudin 18.2 monoclonal antibodies are a promising class of therapeutic agents targeting the Claudin 18.2 protein, a tight junction protein that is highly expressed in various cancers, including gastric, pancreatic, and ovarian cancers. In normal tissues, Claudin 18.2 is predominantly expressed in differentiated gastric mucosal cells, but its upregulation in tumor cells makes it an attractive target for cancer therapy. These monoclonal antibodies, such as Zolbetuximab, work by binding specifically to the extracellular domain of Claudin 18.2, inducing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to kill cancer cells.
相關(guān)分類(lèi)
該廠商的其他產(chǎn)品
- S0B6045 Anti-IL-23 monoclonal antibody(Mirikizumab)
- S0B1302 Anti-Human PD1 Monoclonal Antibody (Tislelizumab)
- S0E0022 Anti-Human TL1A Monoclonal Antibody (PF-06480605)
- S0E0021 Anti-human TL1A Monoclonal Antibody (Duvakitug)
- S0E0020 Anti-human TL1A Monoclonal Antibody(Tulisokibart)
- S0B0980 Anti-PD-1 Monoclonal Antibody(Tislelizumab)
- S0E0018 Anti-DLL3 Monoclonal Antibody(Rovalpituzumab)
- S0B060 Anti-CD49d Monoclonal Antibody(Natalizumab)